Literature DB >> 31949741

Aberrant RASSF5 gene transcribed region hypermethylation in pediatric hepatoblastomas.

Gongbao Liu1, Baihui Liu1, Shan Zheng1, Kuiran Dong1, Rui Dong1.   

Abstract

BACKGROUND: Aberrant DNA methylation plays an important role in cancer and has been recognized to contribute to the activity of oncogenes and inactivity of tumor suppressor genes. RAS association domain family (RASSF) members have been shown to be epigenetically silenced by promoter methylation in cancers, including hepatoblastoma.
METHODS: We assessed the methylation patterns in the gene of RASSF5 from hepatoblastoma tissue samples harvested from patients using high-throughput mass spectrometry on a matrix-assisted laser desorption/ionization time-of-flight mass array.
RESULTS: Hypermethylation was found in the RASSF5 gene transcribed regionand was correlated with downregulation of RASSF5 RNA expression levels in the hepatoblastoma samples.
CONCLUSIONS: The results indicate that aberrant methylation of RASSF5 may contribute to its downregulated mRNA expression in hepatoblastoma. IJCEP
Copyright © 2018.

Entities:  

Keywords:  RASSF5; hepatoblastoma; methylation

Year:  2018        PMID: 31949741      PMCID: PMC6962826     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  29 in total

1.  Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia.

Authors:  Lirong Pei; Jeong-Hyeon Choi; Jimei Liu; Eun-Joon Lee; Brian McCarthy; James M Wilson; Ethan Speir; Farrukh Awan; Hongseok Tae; Gerald Arthur; Jennifer L Schnabel; Kristen H Taylor; Xinguo Wang; Dong Xu; Han-Fei Ding; David H Munn; Charles Caldwell; Huidong Shi
Journal:  Epigenetics       Date:  2012-06-01       Impact factor: 4.528

2.  Hepatoblastoma and low birth weight.

Authors:  Logan G Spector; James H Feusner; Julie A Ross
Journal:  Pediatr Blood Cancer       Date:  2004-11       Impact factor: 3.167

Review 3.  Hepatoblastoma: recent developments in research and treatment.

Authors:  Dietrich von Schweinitz
Journal:  Semin Pediatr Surg       Date:  2012-02       Impact factor: 2.754

4.  NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers.

Authors:  Luke Hesson; Ashraf Dallol; John D Minna; Eamonn R Maher; Farida Latif
Journal:  Oncogene       Date:  2003-02-13       Impact factor: 9.867

Review 5.  The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds.

Authors:  Barbara A Hirschman; Brad H Pollock; Gail E Tomlinson
Journal:  J Pediatr       Date:  2005-08       Impact factor: 4.406

6.  Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma.

Authors:  Mark R Morris; Luke B Hesson; Kate J Wagner; Neil V Morgan; Dewi Astuti; Robert D Lees; Wendy N Cooper; JouAnn Lee; Dean Gentle; Fiona Macdonald; Takeshi Kishida; Richard Grundy; Masahiro Yao; Farida Latif; Eamonn R Maher
Journal:  Oncogene       Date:  2003-10-02       Impact factor: 9.867

7.  Genome-wide analysis of DNA methylation in hepatoblastoma tissues.

Authors:  Ximao Cui; Baihui Liu; Shan Zheng; Kuiran Dong; Rui Dong
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

8.  Maternal and infant birth characteristics and hepatoblastoma.

Authors:  Colleen C McLaughlin; Mark S Baptiste; Maria J Schymura; Philip C Nasca; Michael S Zdeb
Journal:  Am J Epidemiol       Date:  2006-03-01       Impact factor: 4.897

9.  RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.

Authors:  Shohei Honda; Hisayuki Miyagi; Hiromu Suzuki; Masashi Minato; Masayuki Haruta; Yasuhiko Kaneko; Kanako C Hatanaka; Eiso Hiyama; Takehiko Kamijo; Tadao Okada; Akinobu Taketomi
Journal:  Pediatr Surg Int       Date:  2013-11       Impact factor: 1.827

10.  NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.

Authors:  Doris Macheiner; Christine Gauglhofer; Chantal Rodgarkia-Dara; Michael Grusch; Andreas Brachner; Christoph Bichler; Daniela Kandioler; Hedwig Sutterlüty; Wolfgang Mikulits; Rolf Schulte-Hermann; Bettina Grasl-Kraupp
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.